Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$4.42 +7.3%	$3.40	$2.01 ▼ $5.64	$274.09M	1.52	1.21 million shs	1.92 million shs
FENC Adherex Technologies	$8.92 +2.4%	$7.99	$3.96 ▼ $9.30	$240.40M	0.39	92,327 shs	48,846 shs
PMVP PMV Pharmaceuticals	$1.34 +0.8%	$1.04	$0.81 ▼ $1.82	$69.10M	1.49	198,733 shs	279,702 shs
VOR Vor Biopharma	$2.12 -5.4%	$0.74	$0.13 ▼ $3.29	$280.54M	2.04	4.84 million shs	12.51 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+7.28%	+8.33%	+14.51%	+55.09%	+70.00%
FENC Adherex Technologies	+2.41%	+0.34%	+9.18%	+75.59%	+32.54%
PMVP PMV Pharmaceuticals	+0.75%	+3.88%	+25.23%	+31.37%	-20.24%
VOR Vor Biopharma	-5.36%	-16.54%	+856.25%	+226.15%	+109.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.2388 of 5 stars	3.4	0.0	2.0	0.0	0.6
FENC Adherex Technologies	2.4611 of 5 stars	3.6	1.0	2.9	3.3	0.0
PMVP PMV Pharmaceuticals	3.1491 of 5 stars	3.5	3.0	3.3	2.5	0.6
VOR Vor Biopharma	3.88 of 5 stars	4.3	5.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	164.71% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	45.74% Upside
PMVP PMV Pharmaceuticals	3.00	Buy	$5.50	310.45% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	165.50% Upside

Current Analyst Ratings Breakdown

Latest PMVP, CRDF, FENC, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	432.45	N/A	N/A	$1.86 per share	2.38
FENC Adherex Technologies	$47.54M	5.18	$0.03 per share	269.69	($0.21) per share	-42.48
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$3.40 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
PMVP PMV Pharmaceuticals	-$58.71M	-$1.18	N/A	N/A	N/A	N/A	-32.54%	-29.59%	8/6/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PMVP, CRDF, FENC, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/14/2025	Q2 2025	PMVP PMV Pharmaceuticals	-$0.39	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/9/2025	Q1 2025	PMVP PMV Pharmaceuticals	-$0.37	-$0.34	+$0.03	-$0.34	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
FENC Adherex Technologies	N/A	5.13	4.97
PMVP PMV Pharmaceuticals	N/A	16.75	16.75
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FENC Adherex Technologies	55.51%
PMVP PMV Pharmaceuticals	90.20%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
FENC Adherex Technologies	11.76%
PMVP PMV Pharmaceuticals	7.57%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
PMVP PMV Pharmaceuticals	50	51.95 million	48.02 million	Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

PMVP, CRDF, FENC, and VOR Headlines

Recent News About These Companies

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

1 hour ago | globenewswire.com

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)

July 10, 2025 | americanbankingnews.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63

July 8, 2025 | americanbankingnews.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30, 2025 | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30, 2025 | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30, 2025 | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

Vor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

June 27, 2025 | marketbeat.com

Vor, with new CEO, changes course to target autoimmune disease

June 26, 2025 | biopharmadive.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP, CRDF, FENC, and VOR Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$4.42 +0.30 (+7.28%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$4.43 +0.01 (+0.23%)

As of 09:01 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Adherex Technologies NASDAQ:FENC

$8.92 +0.21 (+2.41%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$8.92 0.00 (0.00%)

As of 07/16/2025 04:04 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

PMV Pharmaceuticals NASDAQ:PMVP

$1.34 +0.01 (+0.75%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.01 (+0.67%)

As of 04:16 AM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Vor Biopharma NYSE:VOR

$2.12 -0.12 (-5.36%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+0.94%)

As of 09:00 AM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time